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Context: Long-term data on enzyme replacement treatment of hypophosphatasia (HPP) are
limited.
Objective: To evaluate efficacy and safety of asfotase alfa in patients aged #5 years with HPP
followed for up to 6 years.
Design: Phase 2 open-label study (July 2010 to September 2016).
Setting: Twenty-two sites; 12 countries.
Participants: Sixty-nine patients [median (range) age: 16.0 (0.02 to 72) months] with severe HPP and
sign/symptom onset before age 6 months.
Intervention: Asfotase alfa 2 mg/kg three times/week or 1 mg/kg six times/week subcutaneously.
Main Outcome Measures: Primary efficacy measure: Radiographic Global Impression of Change
(RGI-C) score [23 (severe worsening) to13 (complete/near-complete healing)]. Additional outcome
measures: respiratory status, growth, and safety. Post hoc analysis: characteristics of radiographic
responders vs nonresponders at Year 1 (RGI-C: $12 vs ,12).
Results: During median (minimum, maximum) 2.3 (0.02, 5.8) years of treatment, RGI-C scores improved
significantly at Month 6 [12.0 (21.7, 13.0)], Year 1 [12.0 (22.3, 13.0)], and Last Assessment [12.3
(22.7, 13.0); P , 0.0001 all]. Of 24 patients requiring respiratory support at Baseline, 11 (46%) no
longer needed support. Height/weight z scores generally increased. Nine patients died (13%). All
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Abbreviations: AE, adverse event; ALP, alkaline phosphatase; CPAP, continuous positive
airway pressure; HPP, hypophosphatasia; IAR, injection-associated reaction; ISR, injection-
site reaction; max, maximum; min, minimum; NAb, neutralizing antibody; PLP, pyridoxal
50-phosphate; PPi, inorganic pyrophosphate; PTH, parathyroid hormone; RGI-C, Radio-
graphic Global Impression of Change; RSS, Rickets Severity Scale; TEAE, treatment-
emergent adverse event; TNSALP, tissue-nonspecific isoenzyme of alkaline phosphatase.
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patients experienced at least one adverse event; pyrexia was most common. Compared with responders
[n 5 50 (72%)], nonresponders [n 5 19 (28%)] had more severe disease at Baseline and a higher rate of
neutralizing antibodies (NAbs) at Last Assessment.
Conclusions:Most infants/young children given asfotase alfa showed early radiographic and clinical
improvement sustained up to 6 years; radiographic nonresponders had more severe disease and
more frequent NAbs at Last Assessment. (J Clin Endocrinol Metab 104: 2735–2747, 2019)
Hypophosphatasia (HPP) is the rare, inherited, sys-temic, metabolic disease characterized by low ac-
tivity of the tissue-nonspecific isoenzyme of alkaline
phosphatase (TNSALP), which leads to extracellular
accumulation of its substrates, mainly inorganic pyro-
phosphate (PPi) and pyridoxal 50-phosphate (PLP) (1–4).
Increased extracellular levels of PPi inhibit bone miner-
alization and lead to impaired skeletal mineralization in
affected patients and additional rickets-like deformities in
infants and children (2, 4). Reduced dephosphorylation
of PLP, the circulating form of vitamin B6, by TNSALP
has been associated with vitamin B6-responsive seizures
in infants with HPP (3, 5).
Clinical presentation of HPP varies with age at onset,
from in utero to adulthood (2, 6). Characteristic signs,
symptoms, and complications of perinatal and infantile
HPP that are potentially life threatening include re-
spiratory failure, vitamin B6-responsive seizures, chest
deformity, and craniosynostosis; other manifestations
include severe hypercalcemia, nephrocalcinosis, poor
growth, osteomalacia, and bowing of the long bones (2,
5, 7–11). Historically, patients with perinatal and in-
fantile HPP have 58% to 100%mortality during the first
year of life (12–14). The most common causes of death
among infants with HPP is respiratory failure secondary
chest deformity and pulmonary hypoplasia (12, 15).
Asfotase alfa (Strensiq®; Alexion Pharmaceuticals,
Inc., Boston, MA) is a human recombinant TNSALP
enzyme-replacement therapy approved for patients with
pediatric-onset HPP (16). In an open-label study of 11
infants and young children (aged #3 years) with life-
threatening HPP, treatment with asfotase alfa for up to
7 years improvedHPP-related skeletal abnormalities seen
on radiograph, respiratory function, growth, and cog-
nitive and motor function (17, 18). Here we report the
long-term safety and efficacy of asfotase alfa of infants
and children aged #5 years with manifestations of HPP
before age 6 months.
Materials and Methods
Patients
Children aged #5 years with signs or symptoms of HPP
before age 6 months were eligible for enrollment if they had a
documented diagnosis of HPP. Diagnosis of HPP required the
following: total serum alkaline phosphatase (ALP) activity below
the lower limit of normal for age, plasma PLP above the upper
limit of normal (unless the patient was receiving pyridoxine for
seizures), radiographic evidence of HPP (flared and frayed
metaphyses; widened growth plates; areas of radiolucency or
sclerosis; or severe, generalized osteopenia), and at least two
HPP-related findings (history or presence of nontraumatic
postnatal fracture and/or delayed fracture healing, neph-
rocalcinosis or history of elevated serum calcium, functional
craniosynostosis, respiratory compromise or rachitic chest de-
formity, vitamin B6-responsive seizures, or failure to thrive).
Exclusion criteria were serum calcium or phosphate levels below
the normal range, serum 25(OH) vitamin D levels ,20 ng/mL,
current evidence of a treatable form of rickets, prior treatment
with bisphosphonates, investigational drug treatment within
1 month, or current enrollment in any other study involving a
new drug, device, or treatment of HPP.
The study complied with the Declaration of Helsinki and
International Conference on Harmonization Guideline for
Good Clinical Practice and with national, state, and local laws
of pertinent regulatory authorities. The protocol was approved
by each site’s Institutional Review Board/independent Ethics
Committee, and written, informed consent was obtained for all
patients from a parent(s) or guardian(s).
Study design
In this open-label, multicenter, single-arm, multinational
study [ClinicalTrials.gov NCT01176266; European Union
Drug Regulating Authorities Clinical Trials (EudraCT) 2010-
019850-42], eligible patients received a total subcutaneous dose
of 6 mg/kg/week of asfotase alfa, administered as 1 mg/kg six
times per week or 2 mg/kg three times per week (maximum
volume: 1 mL asfotase alfa per injection). Dose adjustments
were allowed at the investigator’s discretion to account for
changes in body weight or in consultation with the medical
monitor for safety concerns or lack of efficacy. The maximum
dose permitted was 40 mg per injection or 9 mg/kg/week in
Australia, France, Germany, Italy, Saudi Arabia, Spain, and the
United Kingdom per protocol amendment; no dose restrictions
were applied in Canada, Japan, Russia, Turkey, or the United
States. The initial dose of asfotase alfa was administered at the
study site during the Baseline visit; post-Baseline injections
could be administered at home by a parent, legal guardian, or
designee after adequate training. With each injection, the
designated individual was required to complete a worksheet
regarding the patient’s health condition, any new medications,
and details of the injection. Study visits were scheduled at
Weeks 3 and 6; Months 3, 6, 9, 12, 15, 18, and 24; and every
6 months thereafter until the end-of-study assessment (Month
48 in patients enrolled in the United Kingdom and final, every
6-month assessment in other countries). Patients were enrolled
starting 22 July 2010, and the last patient completed the study
26 September 2016.
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Outcomes measures
Primary efficacy measure
The primary efficacy measure was improvement of HPP-
related skeletal manifestations atWeek 24 (Month 6) andWeek
48 (Year 1) of treatment, as measured on the Radiographic
Global Impression of Change (RGI-C) scale (19). The RGI-C
(19) is a validated seven-point scale that assesses changes from
Baseline in HPP-related skeletal abnormalities: 23 5 severe
worsening, 22 5 moderate worsening, 21 5 minimal wors-
ening, 05 no change,115minimal healing,125 substantial
healing, and 13 5 complete or near-complete healing. Ra-
diographs of the chest, bilateral wrists, and bilateral knees were
reviewed by three independent pediatric radiologists, and
comparisons with Baseline were scored. The mean RGI-C score
for each patient at each time point was calculated from available
scores. The radiologists were blinded to post-Baseline time-
points and all other patient information.
Secondary efficacy measures
Skeletal manifestations of HPP over time. RGI-C scores
and change from Baseline in Rickets Severity Scale (RSS) (20)
scores were assessed at all study visits starting at Month 3. The
RSS (20) is a 10-point scale [05 absence of metaphyseal cupping
and fraying (both characteristic of rickets) to 105 severe rickets;
maximum of four points for the wrists and six points for the
knees] originally developed to assess the severity of nutritional
rickets in the wrists and knees. Radiographs for determination of
RSS score were read by a single independent rater who developed
the RSS (Thomas D. Thacher, MD, Mayo Clinic, Rochester,
MN). The percentage of responders (individual mean RGI-C
score: $12) at each study visit was also determined.
Respiratory status. Respiratory status (including use and type
of support) was assessed at Screening, Baseline, and all sub-
sequent study visits.
Growth. Length/height, weight, and head circumference were
recorded during physical examinations at required study visits
to assess changes in growth. Length/height and weight z scores
were assigned based on the Centers for Disease Control and
Prevention growth charts for age- and sex-matched healthy
infants and children (21). Head circumference z scores were
calculated using World Health Organization formulae (22).
Ventilator-free and overall survival. Ventilator-free survival
was assessedwith the occurrence of death and ventilatory support
[continuous positive airway pressure (CPAP), bilevel or biphasic
positive airway pressure, or mechanical ventilation (invasive
ventilation via endotracheal intubation or tracheostomy)]. Sup-
plemental oxygen was considered respiratory but not ventilatory
support. Survival was monitored throughout the study.
Other measures
Blood samples were collected to assess serum ALP activity,
plasma PPi and PLP, and serum parathyroid hormone (PTH)
concentrations at required study visits after an overnight fast
and before study drug administration.
ALPL gene mutation analysis for patients not previ-
ously tested was performed by Connective Tissue Gene Tests
(Allentown, PA).
Safety and tolerability
Safety was assessed by routine reporting of adverse events
(AEs), which included serious AEs, injection-site reactions
(ISRs), and injection-associated reactions (IARs). ISRs were
defined as treatment-emergent AEs (TEAEs) that were localized
to the site of study drug administration, occurred at any time
point after study drug initiation, and were assessed by the in-
vestigator as possibly, probably, or definitely related to study
drug. IARs were defined as systemic signs, symptoms, or
findings that occurred within 3 hours after study drug ad-
ministration and were assessed by the investigator as possibly,
probably, or definitely related to study drug. AEs of special
interest included ectopic calcifications, lipodystrophy, cranio-
synostosis, and chronic hepatitis and were based on clinical
review of observed AEs. Additional safety assessments included
physical examinations, clinical laboratory tests (including cal-
cium and magnesium), anti-asfotase alfa antibody levels (PPD
Laboratories, LLC, Richmond, VA), fundoscopic eye exami-
nations, and renal ultrasounds. The clinical significance of
abnormal laboratory findings was judged by the investigator.
Safety events reported after the study ended were not included.
Responder analysis
A post hoc analysis compared Baseline characteristics of
responders by radiography (RGI-C score: $12) with those of
nonresponders (score: ,12) at Year 1 of treatment.
Statistical analysis
All efficacy and safety analyses were performed on the full
analysis population (patients who received $1 dose of asfotase
alfa). Some analyses were repeated on the per-protocol pop-
ulation (patients who received any asfotase alfa and had no
major protocol deviations that could influence treatment effect).
In general, continuous variables were summarized descriptively
(data reported herein are median [minimum, maximum (min,
max)] unless otherwise specified), and categorical variables
were summarized by counts and percentages of patients.
For the primary efficacy analysis (RGI-C scores at Month 6
and Year 1), a nonparametric Wilcoxon signed-rank test was
used to determine whether the median RGI-C scores atMonth 6
and Year 1 differed from 0. Missing values were imputed using
last observation carried forward. Patients with no recorded
post-Baseline values were assigned as having no change
(score: 0).
Secondary efficacy analyses of RGI-C scores, percent of
responders, and change from Baseline in RSS scores at each
study visit were conducted in a manner similar to that used for
the primary analysis; however, only observed data were used
(no imputation). P values for length/height and weight z score
were calculated post hoc using the nonparametric Wilcoxon
signed-rank test comparing median change with zero. Phar-
macodynamic and safety assessments are summarized de-
scriptively. Ventilator-free survival and overall survival time
were assessed using Kaplan-Meier methodology.
For the post hoc responder analysis, P values were calculated
using the exact Wilcoxon rank-sum test for continuous vari-
ables and the Fisher’s exact test for categorical variables.
Missing values at Year 1 were imputed with last observation
carried forward. Patients with no post-Baseline data were
assigned as having no change (score: 0) and considered
nonresponders.
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Results
Patients
In total, 69 patients were enrolled from 22 sites in
12 countries and were included in the full analysis
population, and 57 were included in the per-protocol
population (Fig. 1). Patients were excluded from the per-
protocol population if they did not meet entry criteria or
violated entry criteria (n5 9), if they deviated from study
protocol procedures (n 5 2), if study drug was admin-
istered incorrectly (n 5 2) or not at all (n 5 1), or if an
assessment/procedure was not done (n 5 1; Fig. 1). The
number of patients enrolled in each country was as
follows: Australia (n5 1), Canada (n5 11), France (n5
5), Germany (n5 13), Italy (n5 2), Japan (n5 5), Russia
(n5 1), Saudi Arabia (n5 1), Spain (n5 1), Turkey (n5
4), United Kingdom (n 5 4), and United States (n 5 21).
Baseline demographic and clinical characteristics are
summarized in Table 1.
Dosing
Nearly all patients [67/69 (97%)] started asfotase
alfa at 6 mg/kg/week; of the 67 patients, 64 (96%)
received 2 mg/kg three times per week and three
(4%) received 1 mg/kg six times per week. One patient
started at 2 mg/kg seven times per week, and another
started at 3 mg/kg three times per week. Doses were
increased or decreased to 3 to 28 mg/kg/week for 17/69
(25%) patients to account for changes in body weight,
to enhance the likelihood of a clinical response, or
because of AEs and administration issues (volume and
number of injections).
Overall, median treatment duration was 2.3 (0.02,
5.8) years. Of the 69 patients in the full analysis pop-
ulation, three (4%) received treatment for ,3 months
and 14 (20%) for $36 months.
Primary efficacy measure
At Month 6 of treatment, the median (min, max)
RGI-C score indicated significant improvement [12.0
(21.7, 13.0); P , 0.0001; n 5 69]; most patients [40/
69 (58%)] were considered responders, and six (9%)
achieved a score of 13, indicating complete or near-
complete healing of HPP-related skeletal manifestations.
Results observed at Month 6 were consistent with those
at Year 1 [12.0 (22.3, 13.0); P , 0.0001; n 5 69]; 50/
69 (72%) patients were considered responders, of which
four (6%) achieved a score of13. Results were similar in
the per-protocol population (data not shown).
Secondary efficacy measures
Skeletal manifestations of HPP over time
Preliminary patient-level radiographic outcomes have
been published (14). Significant (P , 0.05) improve-
ments in RGI-C score were observed at Months 3 and 6;
Years 1, 2, 3, 4, and 5; and Last Assessment (Fig. 2). The
proportion of patients classified as responders (RGI-C
score$12) increased during the study, from 36% (24/66
patients) at Month 3% to 73% (49/67 patients) at Last
Assessment. Consistent with RGI-C scores, RSS scores
improved significantly (P , 0.05) from Baseline at
Months 3 and 6; Years 1, 2, 3, 4, and 5; and Last As-
sessment (Fig. 3). Results were similar in the per-protocol
population (data not shown).
Respiratory status
Of the 45/69 (65%) patients who did not require
respiratory support at Baseline, 38 (84%) lived without
support during the study and 43 (96%) did not require
support at the Last Assessment; one patient was re-
ceiving supplemental oxygen at Year 4, and one was
receiving CPAP at Month 6. Three patients developed
the need for respiratory support after Baseline but were
weaned before Last Assessment (by Month 9, Year 1.5,
and Year 2.5). Of the 24/69 (35%) patients who re-
quired respiratory support at Baseline (including in-
vasive mechanical ventilation, CPAP, or supplemental
oxygen), 11 (46%) no longer required support at Last
Assessment.
Figure 1. Patient disposition. aAll patients who received any
asfotase alfa, regardless of whether they were lost to follow-up or
dropped out of the study. bAll patients from the full analysis
population who did not have any major protocol deviations deemed
potentially to influence treatment effect. cOne patient did not meet
the eligibility criteria and had incorrect administration of study drug.
dConsidered possibly related to study drug treatment in one patient.
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Growth
Length/height and weight z score generally improved
over time (Fig. 4). Change from Baseline at Last As-
sessment was significant for both length/height [0.5 (24,
4); n5 66; P5 0.0025] and weight [1.0 (25, 6); n5 67;
P5 0.0001] z score. Baseline head circumference z score
was21.0 (24, 4; n5 56); change from Baseline was 0.1
(22, 3; n 5 47) at Month 6 and 0.2 (23, 7; n 5 55) at
Last Assessment.
Ventilator-free and overall survival
Thirty-eight of the 45 patients (84%) who were not
receiving respiratory support at Baseline remained venti-
lator free. The Kaplan-Meier estimate of the ventilator-free
survival rate at Year 6 for these patients was 84%. Among
all 69 patients, the Kaplan-Meier estimate of the overall
survival rate at Year 6 was 80%. Survival outcomes for
patients in this study were also included in a published
analysis that pooled these data with those of a separate
study (14).
Other measures
Median (min, max) ALP activity increased from 20 (18,
122) U/L at Baseline (n 5 65) to 3761 (272, 11,910) U/L
after 3 weeks of treatment (n 5 61) and continued to in-
crease through Year 1 [6742 (1315, 20,041) U/L; n5 49].
ALP remained elevated throughout treatment, as expected
with asfotase alfa treatment. Median (min, max) PPi
concentration, which was elevated at Baseline [6.3 (2.7,
13.3) mM; n 5 65], decreased to within reference range
(1.3–5.7 mM) at Week 6 [3.9 (0.8, 39.2) mM; n562] and
remained within reference range throughout the study.
Likewise, median (min, max) PLP concentration decreased
from Baseline [521 (48, 24,600) ng/mL; n 5 60] to within
reference range (11.8 to 68.4 ng/mL) at Week 6 [44 (6,
4590) ng/mL; n557] and remained within reference range
Table 1. Baseline Demographic and Clinical Characteristics
Baseline Characteristic Enrolled Patients, n 5 69
Age at enrollment, month, median (min, max) 16.0 (0.3, 72.2)
Sex, n (%)
Male 33 (48)
Race, n (%)
White 54 (78)
Asian 7 (10)
Other 3 (4)
Unknown 5 (7)
Age at first signs of HPP, month, median (min, max) 1.0 (0, 5.5)
HPP-specific medical history, n (%)
Abnormally shaped chest 58 (84)
History of respiratory compromise (up to and including respiratory failure)a 46 (67)
Seizures 17 (25)
Difficulty gaining weight, failure to thrive, and/or difficulty eating/swallowing 60 (87)
Hypercalcemia 61 (88)
Nephrocalcinosis 37 (54)
Fractures and/or delayed fracture healing 21 (30)
Length/height z score n 5 67
Median (min, max) 22.7 (210.0, 1.0)
Weight z score n 5 68
Median (min, max) 22.5 (224.0, 0)
RSS score n 5 67
Median (min, max) 4.0 (0, 10.0)
ALP, U/L (normal range: 60–370 U/L)b n 5 65
Median (min, max) 20 (18, 122)
PPi, mM (normal range: 1.3–5.7 mM) n 5 65
Median (min, max) 6.3 (2.7, 13.3)
PLP, ng/mL (normal range: 11.8–68.4 ng/mL)c n 5 60
Median (min, max) 521 (48, 24,600)
Calcium, mM [normal ranges: 2.25–2.74 mM (age:#2 years); 2.1–2.57 mM (age:.2 years)] n 5 65
Median (min, max) 2.6 (1.8, 4.0)
aRespiratory compromise was defined as respiratory signs/symptoms that required institution of respiratory support measure(s), requiredmedication(s) for
management of symptom(s), and/or were associated with other respiratory complications (e.g., pneumonia, respiratory tract infection).
bNormal range for ALP activity, per ARUP Laboratories (University of Utah, Salt Lake City, UT), varies by age: 0–30 days: 60–320U/L; 1–11months: 70–350
U/L; 1–3 years: 125–320 U/L; 4–6 years: 150–370 U/L. Normal range also varies by sex in patients older than 10 years of age.
cMedian (min, max) concentration for patients receiving vitamin B6 supplementation before dosing (n5 14) was 9960 (65, 24,600) ng/mL and for those
patients not receiving vitamin B6 supplementation before dosing (n 5 46) was 417 (48, 13,100) ng/mL.
doi: 10.1210/jc.2018-02335 https://academic.oup.com/jcem 2739
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article-abstract/104/7/2735/5364747 by Biblioteca D
e H
um
anidades user on 14 O
ctober 2019
through Year 5. PTH levels were 1.2 (0.6, 6.7; n5 48) pM
at Baseline, 1.7 (0.6, 45.9; n5 52) pM atMonth 6 and 2.2
(0.6, 10.1; n 5 66) pM at Last Assessment.
Sixty-two patients had ALPL mutation analysis re-
sults; 44 patients were compound heterozygous for two
pathogenic mutations, nine were homozygous for the
same mutant allele, and nine had only one mutation
identified, consistent with a dominant-negative effect.
Safety and tolerability
All patients experienced at least one TEAE. Table 2
summarizes the most common TEAEs occurring
in $20% of patients, regardless of the relationship
to study drug. Most TEAEs were mild [2125/3052
(70%)] or moderate [728/3052 (24%)] in severity and
assessed by the investigator as unrelated to study drug
[2409/3052 (79%)]. The most common TEAEs assessed
as related to study drug were ISRs [593/643 (92%)] and
IARs [11/643 (2%)], which occurred in 43 and six
patients, respectively. The most common ISRs were
injection-site erythema [33/69 (48%)], discoloration
[12/69 (17%)], induration [11/69 (16%)], and hema-
toma [10/69 (14%)]. IARs consisted of pyrexia [4/69
(6%)], chills [1/69 (1%)], injection-site rash [1/69 (1%)],
Figure 2. Median RGI-C scores over time in infants and children with HPP treated with asfotase alfa. Patients with RGI-C scores of $12 were
classified as responders. RGI-C scale: 23 5 severe worsening of HPP-related skeletal manifestations; 22 5 moderate worsening; 21 5 minimal
worsening; 0 5 no change; 11 5 minimal healing; 12 5 substantial healing; 13 5 complete or near-complete healing. aMonth 6 and Year 1
values differ from those in the text for the primary efficacy measure, as no imputation of missing values was performed. bLast Assessment was
defined as the latest post-Baseline assessment on treatment (within 5 days after end of treatment) with a nonmissing value for each patient;
overall median (min, max) treatment duration was 2.3 (0.02, 5.8) years. cAll patients were included in the full analysis population; the decreasing
n is a result of the number of patients on treatment at the end of the study or because assessments may not have been done at each time
point. *P , 0.01 based on Wilcoxon signed-rank test comparing median change with zero.
Figure 3. Median change from Baseline in RSS scores over time in infants and children with HPP treated with asfotase alfa. aLast Assessment
was defined as the latest post-Baseline assessment on treatment (within 5 days after end of treatment) with a nonmissing value for each patient;
overall median (min, max) treatment duration was 2.3 (0.02, 5.8) years. bAll patients were included in the full analysis population; the decreasing
n is a result of the number of patients on treatment at the end of study or because assessments may not have been done at each time point.
*P , 0.05 based on Wilcoxon signed-rank test comparing median change with zero.
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anaphylactoid reaction [1/69 (1%)], drug hypersensi-
tivity [1/69 (1%)], and papular rash [1/69 (1%)]. The
IARs of anaphylactoid reaction (categorized as Stage 1
anaphylactic shock) and drug hypersensitivity were
considered serious; neither patient had received pre-
treatment with medications to manage IARs. Both
events resulted in interruption of asfotase alfa admin-
istration; the anaphylactoid reaction was treated with
an IV electrolyte solution, and no treatment was given
for the event of drug hypersensitivity. Both events re-
solved, and treatment with asfotase alfa was restarted
without further occurrences.
Lipodystrophy was reported in 5/69 (7%) patients and
was mild or moderate in severity and assessed as prob-
ably related or related to study drug. Eight patients [8/69
(12%)] had ectopic calcification findings on an eye ex-
amination, which were identified as TEAEs in two
patients. Both events involved corneal deposits, were
Figure 4. Median (min, max) z scores for (A) length/height and (B) weight over time in infants and children with HPP treated with asfotase alfa.
aLast Assessment was defined as the latest post-Baseline assessment on treatment (within 5 days after the end of the study treatment) with a
nonmissing value for each patient; overall median treatment duration was 2.3 (0.02, 5.8) years. bAll patients were included in the full analysis
population; the decreasing n is a result of the number of patients on treatment at the end of the study or because assessments may not have
been done at each time point. *P , 0.05 based on Wilcoxon signed-rank test comparing median change with zero.
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considered unrelated to study drug, did not interfere with
vision, and resolved at Last Assessment. Nephrocalcinosis
was reported in 46/69 (67%) patients and was present at
Baseline in all but six patients. Five patients had neph-
rocalcinosis reported as a TEAE. An additional seven had
eight TEAEs that were not recorded as ectopic calcifica-
tions or nephrocalcinosis but were considered as such
upon medical review. Renal function remained normal in
all patients.
A total of 28/69 (41%) patients experienced 46 events
related to craniosynostosis (onset after start of treatment:
1 to 1851 days); all but three events were assessed as
unlikely related or unrelated to study drug, and all but
seven were mild or moderate in severity. Two patients
required surgical treatment.
Twenty-two events related to chronic hepatitis were
reported in 13/69 (19%) patients. All were mild or
moderate in severity. Hepatomegaly in one patient was
assessed as possibly related to study drug treatment. A
serious AE of increased hepatic enzymes in another pa-
tient was moderate in severity and assessed as unlikely
related to study drug.
A total of 50/69 (72%) patients experienced 297 se-
rious AEs, most of which [286 (96%)] were assessed by
the investigator as unlikely related or unrelated to the
study drug. Of the 11 serious AEs considered treatment
related, seven were ISRs or IARs in three patients. The
remaining four occurred in three patients: craniosynos-
tosis (n 5 1), pneumonia resulting in study-drug with-
drawal (n 5 1), and Arnold-Chiari type 1 malformation
and syringomyelia (n 5 1).
In total, nine (13%) patients died. The causes of death
in six patients were respiratory failure and cerebral
death (following findings of hypoxia-induced lesions/
encephalopathy 1 week before death); HPP-related
complications; severe respiratory failure; cardiopulmo-
nary arrest; severe cardiopulmonary insufficiency; and
transtentorial and cerebellar tonsillar herniation as a
result of cerebral edema related to severe HPP. Three
patients died of pneumonia; in one patient, pneumo-
nia was considered possibly related to asfotase alfa
treatment.
Calcium and magnesium levels were of particular
interest in this study population based on their role in
bone formation, strength, and rigidity. The mean calcium
level was within normal limits at Baseline [mean (SD): 2.6
(0.3) mM], and only small fluctuations were observed
over the course of the study. Post-Baseline changes in
calcium levels were considered clinically significant by
the investigator in six patients; three patients had ele-
vated levels [3.6 mM atWeek 3 (n5 1); 3.6 mM atWeek
3 and 3.3 mM at Week 6 (n 5 1); and 3.1 mM at Week
120 (n 5 1)], two of whom had elevated levels
at Baseline, and three had decreased levels [2.1 mM at
Month 3 (n 5 1; age at Baseline: 217 weeks); 2.0 mM at
Month 9 (n 5 1; age at Baseline: 21 weeks); and 2.2 mM
at Year 1 (n 5 1; age at Baseline: 4 weeks)]. Magnesium
levels remained generally within normal range; one patient
had a clinically significant low level at Month 3 (0.5 mM)
that was normalized atMonths 6 and 9 (Last Assessment).
Twelve patients had clinically significant abnormal
hematology findings. Five had low hematocrit and he-
moglobin levels, five had high leukocyte or lymphocyte
counts, one had low neutrophil count, and one had high
blasts. For most patients, hematology findings returned
to normal or were no longer considered clinically sig-
nificant at the patient’s Last Assessment; one patient had
clinically significant low hematocrit, hemoglobin, and
erythrocyte levels at Years 3.5 and 4 (Last Assessment).
Anti-asfotase alfa antibody levels
In total, 60/68 (88%) patients tested positive for anti-
asfotase alfa antibodies during the study (maximum titer:
2048); 40 (67%) of these patients tested positive for
neutralizing antibodies (NAbs). Six patients tested pos-
itive for anti-asfotase alfa antibodies at Baseline, one of
whom tested negative at all subsequent assessments. The
median (min, max) positive NAb titer at Last Assessment,
measured as percent inhibition, was 7.7% (4.5, 92.6).
Median (min, max) time to detection of first post-
Baseline NAb titer was 168.5 (20, 1359) days. No
clear relationship was found between the presence of
anti-asfotase alfa antibodies and AEs nor were any AEs
suggestive of immune mediation or tachyphylaxis.
RGI-C responders
Results of the post hoc comparison between RGI-C
responders (individual mean $12 at Year 1) and
Table 2. TEAEs Occurring in >20% of
Patients—Safety Analysis Population (n569)
TEAEa Patients, n (%)
Pyrexia 47 (68)
Tooth loss 41 (59)
Injection-site erythema 33 (48)
Vomiting 31 (45)
Diarrhea 20 (29)
Craniosynostosis 19 (28)
Upper respiratory tract infection 19 (28)
Nasopharyngitis 18 (26)
Gastroenteritis 17 (25)
Cough 17 (25)
Respiratory tract infection 16 (23)
Constipation 16 (23)
Pneumonia 14 (20)
aAEs coded using MedDRA Version 13.0 (Medical Dictionary for Reg-
ulatory Activities, McLean, VA).
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nonresponders at Week 48 are summarized in Table 3. Of
the 69 patients in this study, 50 (72.5%) had an RGI-C
score of $12 at Year 1. Nineteen patients did not achieve
an RGI-C score of$12 at Year 1; median RGI-C score for
these nonresponders was 0.67 at Year 1. Seventeen of these
nonresponders had a last overall on-treatment assessment,
and of these, five achieved anRGI-C score of$12 by;2.3
years. In this same timeframe, an additional four non-
responders achieved anRGI-C score between11 and,12.
The remaining eight nonresponders hadRGI-C scores,11
at Last Assessment.
A greater proportion of responders than non-
responders completed the study (94% vs 68%, re-
spectively; P 5 0.0105), with fewer deaths (4% vs 37%,
respectively; P 5 0.0012). Compared with responders,
nonresponders also had higher serum calcium (P 5
0.0204), plasma PLP (P 5 0.0403), and plasma PPi
concentrations (P5 0.0427) at Baseline. Nonresponders
had lower length/height z scores (P 5 0.0345) and
smaller chest circumferences (P 5 0.0261) at Baseline
than responders. Correlation between Baseline ALP ac-
tivity and RGI-C score at Year 1 was moderate in
nonresponders (Pearson correlation coefficient: 0.5468;
P 5 0.0189) and weak in responders (0.2008; P 5
0.1759). There was no statistical difference between
responders and nonresponders in anti-asfotase alfa an-
tibody status during the study. Positive NAb status
was not statistically significantly different between re-
sponders and nonresponders atMonth 6 or at Year 1, but
the percentage of nonresponders positive for NAbs was
significantly higher (9/15; 60%) than the percentage of
responders (9/45; 20%; P5 0.0047) at Last Assessment.
Discussion
This open-label study of asfotase alfa treatment in infants
and young children with a follow-up period of up to 6
years is the largest prospective clinical study of HPP to
date. The enrolled population of 69 children with severe
HPP is exceptionally large for a study of a rare disease
such as HPP. This study assessed therapy response,
showing that asfotase alfa was efficacious and safe in the
majority of children who had onset of severe HPP signs/
symptoms before age 6months. Improvements in skeletal
manifestations, respiratory support, and growth were
observed during treatment with asfotase alfa within
6 months and were sustained for a median of 2.3 years
and up to 6 years of treatment. Radiographic non-
responders at Year 1 generally had more severe disease at
Baseline and a higher incidence of positive NAb status at
the study end than responders.
The primary efficacy measures at Month 6 and Year 1
were met, showing substantial improvements in HPP-related
skeletal manifestations. Moreover, 58% of patients were
considered responders at Month 6 and 72% at Year 1,
indicating substantial healing of skeletal manifestations.
Improvements in respiratory status were also observed;
nearly one-half (46%) of the patients who started the study
requiring respiratory support were able to forego support by
Last Assessment, and 89% who were free of respiratory
support at Baseline remained so over the study. These results
are consistent with those of previous smaller studies in in-
fants and young children (n 5 11; age: 2 weeks to 3 years)
and in Japanese patients with HPP [n 5 13; median (min,
max) age at Baseline: 91 days (0 days, 34 years)] (17, 18, 23).
Nine deaths occurred in this study, mostly attributed
to underlying HPP disease. The majority of deaths (78%)
were radiographic nonresponders. One death, which was
attributed to pneumonia, was considered by the in-
vestigator to be possibly related to asfotase alfa. In a prior
survival analysis, which included data from some pa-
tients in the current study and other asfotase alfa studies,
treatment significantly (P , 0.0001) improved survival
among patients with perinatal and infantile HPP; sur-
vival was 95% at age 1 year and 84% at age 5 years but
only 42% and 27%, respectively, among historical con-
trols (14).
Asfotase alfa was generally well tolerated, with an
overall safety profile consistent with that observed pre-
viously (14, 17, 23). All patients experienced at least one
TEAE; most TEAEs were mild or moderate in severity
and assessed as unrelated to study drug. Less than 10%
of patients experienced serious AEs that were considered
treatment related. The majority (64%) of treatment-
related serious AEs were ISRs or IARs. Clinicians
should be aware of strategies to minimize or prevent
ISRs, such as proper injection technique, as well as
management options for reactions requiring treatment
(24). Post-Baseline elevated calcium levels were consid-
ered clinically significant in three patients, two of whom
had clinically significant elevations at Baseline. Three
patients had clinically significant hypocalcemia during
the study. Previous reports discussed the role of dietary
calcium restriction in the management of HPP before
asfotase alfa became available, as many patients have a
history of hypercalcemia (17, 23). The improved skeletal
mineralization associated with asfotase alfa increases
calcium intake requirements (i.e., hungry bone syn-
drome). Hence, the supplying of sufficient dietary cal-
cium and monitoring of serum calcium and PTH during
initial treatment are essential (24). The monitoring of
urine calcium in relation to serum calcium and PTH is
also important in the guidance of calcium requirements.
Anti-asfotase alfa antibodies were identified in 88% of
patients during this study, and 67% of these patients
tested positive for NAbs. Development of antidrug
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Table 3. Comparison of Baseline Characteristics and Outcomes in Radiographic Responders vs
Nonrespondersa—Full Analysis Population
Responders
(n 5 50)b
Nonresponders
(n 5 19)b P Value
Disposition
Completed study, n (%) 47 (94) 13 (68) 0.0105
Discontinued, n
Withdrawal by parents 1 2
AE 2 4
Characteristics
Age at enrollment, month, median (min, max) 21.0 (0, 71.4) 8.9 (0.4, 71.7) 0.2318
Male, n (%) 25 (50) 8 (42) 0.5997
Age at HPP onset, month, median (min, max) 1.0 (0, 5.5) 1.0 (0, 5.0) 0.1164
Time from HPP diagnosis to treatment, month,
Median (min, max)
20.3 (0, 67.8) 8.1 (0.3, 67.3) 0.3753
Weight z score n 5 49 n 5 19
Median (min, max) 22.3 (27.8, 20.04) 22.7 (223.8, 20.3) 0.3930
Length z score n 5 48 n 5 19
Median (min, max) 22.6 (28.3, 0.9) 23.5 (210.1, 20.3) 0.0345
Chest circumference, cm n 5 47 n 5 19
Median (min, max) 42.5 (32.0, 56.0) 37.0 (27.5, 51.5) 0.0261
Race, n (%)
Asian 5 (10.0) 2 (10.5) 1.0000
White 38 (76.0) 16 (84.2)
Multiple 1 (2.0) 0
Other 2 (4.0) 0
Unknown/not reported 4 (8.0) 1 (5.3)
Laboratory parameters, median (min, max)
ALP, U/L n 5 47 n 5 18
23 (18, 122) 18 (18, 50) 0.0513
Calcium, mM n 5 47 n 5 18
2.5 (1.8, 3.6) 2.6 (2.3, 4.0) 0.0204
PLP, ng/mL n 5 43 n 5 17
429.0 (65.1, 24,100.0) 1300.0 (47.5, 24,600.0) 0.0403
PPi, mM n 5 46 n 5 19
5.9 (2.7, 12.5) 7.1 (3.6, 13.3) 0.0427
Magnesium, mM n 5 47 n 5 18
0.9 (0.6, 1.2) 0.9 (0.6, 1.1) 0.6433
Phosphate, mM n 5 47 n 5 18
2.0 (1.2, 2.5) 2.0 (0.9, 2.7) 0.7918
PTH, pM n 5 34 n 5 14
1.5 (0.6, 5.4) 0.6 (0.6, 6.7) 0.7302
ALPL gene polymorphism, n (%) 0.6634
Compound heterozygous 31/45 (69) 13/17 (76)
Dominant heterozygous 8/45 (18) 1/17 (6)
Homozygous 6/45 (13) 3/17 (18)
Disease characteristics, n (%)
Respiratory compromise 33 (66) 12 (63) 1.000
Rachitic chest 49 (98) 17 (90) 0.1817
B6-responsive seizures 11 (22) 8 (42) 0.1320
Abnormally shaped chest 39 (78) 13 (68) 0.5327
High serum calcium 35 (70) 14 (74) 1.000
Nephrocalcinosis 25 (50) 12 (63) 0.4208
Mean Baseline, mean RSS (SD) 4.7 (3.1) 4.8 (3.5) 0.9833
Respiratory characteristics
Fraction of inspired oxygen, % n 5 12 n 5 7
Median (min, max) 29.0 (21.0, 50.0) 25.0 (21.0, 54.0) 0.3500
Inspiratory pressure, cm H2O n 5 8 n 5 5
Median (min, max) 25.5 (0.4, 31.0) 24.0 (15.0, 32.0) 0.6601
Expiratory pressure, cm H2O n 5 9 n 5 7
Median (min, max) 7.0 (5.0, 12.0) 6.0 (5.0, 8.0) 0.2726
Respiratory support type, n (%)
No support 35 (70) 10 (53) 0.5079
Mechanical ventilation 8 (16) 5 (26)
Supplemental oxygen 4 (8) 2 (11)
(Continued)
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antibodies has been documented in previous clinical
studies of asfotase alfa, with no apparent impact on
clinical outcomes (17, 25). These data reflect small
sample sizes (9 to 12 patients) and a short duration of
treatment exposure (up to 1 year). The current study,
which includes the largest population to date of asfotase
alfa-treated patients, with amedian (min, max) treatment
duration of 2.3 (0.02, 5.8) years, showed no clear re-
lationship between the presence of these antibodies and
AEs. A post hoc analysis suggests that NAb-positive
status may be associated with a slow radiographic re-
sponse, as assessed by the RGI-C at Year 1. Un-
fortunately, antidrug antibody testing is not yet
commercially available to identify patients who may not
be responding to treatment because of the presence of
NAbs. The development of NAbs could be associated
with the severity of the disease, as has been observed in
other conditions, such as infantile-onset Pompe disease
(26), but to date, the limited data available do not allow us
to draw firm conclusions. A recent case report found that
the development of NAbs (percent inhibition: 40.4%) in a
patient with HPP treated with asfotase alfa for 2.5 years
was associated with loss of efficacy and that immune-
tolerance induction therapy and a 1-month discontinua-
tion of asfotase alfa successfully restored treatment effi-
cacy within 6 months (27). Currently, antidrug antibody
Table 3. Comparison of Baseline Characteristics and Outcomes in Radiographic Responders vs
Nonrespondersa—Full Analysis Population (Continued)
Responders
(n 5 50)b
Nonresponders
(n 5 19)b P Value
CPAP 2 (4) 2 (11)
Other 1 (2) 0
Respiratory support duration, hour n 5 14 n 5 8
Median (min, max) 24 (8, 24) 24 (24, 24) 0.4497
Treatment exposure
Dosing frequency, n (%) 0.6642
Always received three times/week 46 (92) 17 (90)
Ever received greater than three times/week 4 (8) 2 (11)
Last dose received,mg/kg/week,median (min,max) 4.0 (2, 12) 5.7 (2, 11) 0.2924
Treatment duration, year, median (min, max) 2.3 (0.6, 5.8) 1.9 (0.02, 4.2) 0.1342
ADA/NAbs
Positive ADA status, n/N (%)
Month 6 34/48 (71) 12/15 (80) 0.7400
Year 1 28/44 (64) 9/10 (90) 0.1411
Ever 45/50 (90) 15/18 (83) 0.4279
Last Assessment 35/50 (70) 14/18 (78) 0.7603
Positive NAb status, n/N (%)
Month 6 10/33 (30) 6/12 (50) 0.2963
Year 1 8/28 (29) 5/9 (56) 0.2293
Ever 29/45 (64) 11/15 (73) 0.7529
Last Assessment 9/45 (20) 9/15 (60) 0.0074
NAb by percent inhibition
Month 6 n = 33 n = 12
Median (min, max) 2.4 (21.7, 90.3) 5.4 (20.5, 88.5) 0.1820
Year 1 n = 3 n = 12
Median (min, max) 2.5 (26.2, 63.5) 4.7 (23.5, 93.8) 0.3046
Death
Number of deaths on study, n (%) 2 (4) 7 (37) 0.0012
RGI-C scores
RGI-C score at Last Assessment n 5 50 n 5 17
Median (min, max) 12.7 (22.7, 13.0) 11.0 (21.7, 12.7) ,0.0001
Category, n (%)
23 to ,22 2/50 (4) 0/17
22 to ,21 0/50 1/17 (6)
21 to ,0 1/50 (2) 4/17 (24)
0 to ,11 0/50 3/17 (18)
11 to ,12 3/50 (6) 4/17 (24)
12 to ,13 40/50 (80) 5/17 (29)
13 4/50 (8) 0/17
Abbreviation: ADA, antidrug antibodies.
aRGI-C responders: mean score $12 at Year 1.
bPercentages of patients are calculated using the total numbers of responders (n550) and nonresponders (n519) in the full analysis population unless
otherwise noted.
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testing is available for patients enrolled in the Global HPP
Registry (NCT02306720; EUPAS13514), which will also
allow for the collection of data to understand further the
impact of NAbs on the efficacy and safety of asfotase alfa.
Generally, RGI-C nonresponders at Year 1 represent a
subgroup of patients with more severe HPP at Baseline,
evidenced by narrower chest walls (i.e., smaller chest
circumference), greater requirements for mechanical
ventilation, and a higher proportion of deaths. Levels of
TNSALP substrates (PPi and PLP) and serum calcium
were also higher in nonresponders. These characteristics
should be considered when determining dosing for
patients with severe perinatal HPP. It should also be
considered that patients with severe disease may have a
delayed response to treatment or, in some cases, a
limited response to treatment as a result of serious pre-
existing complications of HPP, such as severe hypo-
mineralization or lung hypoplasia.
A limitation of this study was the heterogeneity of
study patients, as some patients had life-threatening
perinatal disease. In addition, treatment was initiated
at various ages, making comparisons difficult. Statis-
tical analyses also did not correct for multiplicity or
confounding variables. Lastly, in our post hoc re-
sponder analysis, although there were some patients
who had minimal radiographic improvements, as a
result of our strict definition of responders (RGI-C
score $12), these patients were included in the non-
responder group. Accordingly, nine patients in the
nonresponder group, included based on their RGI-C
scores at Year 1, had scores $11 to ,13 at Last As-
sessment, indicating minimal or substantial healing.
Conclusions
Most infants and young children with HPP treated with
asfotase alfa showed sustained improvements in HPP-
related skeletal manifestations, respiratory function, and
growth. Asfotase alfa was generally well tolerated. A
subgroup of the study patients with very severe disease
at Baseline was classified here as radiographic non-
responders. These patients should be closely monitored
for a therapeutic response, with dose adjustments and
additional therapeutic measures considered as necessary.
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